4 active not recruiting. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 4 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma Tislelizumab, Afatinib, Lysogenic HSV virus. - HNSCC, Lysogenic HSV Virus | Phase 1 / Phase 2 | Active not recruiting | West China Hospital | 29 | 2025-06-10 | 2026-07-01 |
| Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Camrelizumab - Esophageal Neoplasm, Immunotherapy | Phase 1 / Phase 2 | Active not recruiting | Fujian Medical University Union Hospital | 25 | 2021-11-10 | 2025-11-19 |
| Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment Camrelizumab - Urinary Bladder Neoplasms, Immunotherapy | Phase 1 / Phase 2 | Active not recruiting | Fudan University | 25 | 2021-06-09 | 2026-07-20 |
| NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy NBTXR3, SABR, Nivolumab - Radiotherapy, Immunotherapy | Phase 1 | Active not recruiting | Nanobiotix | 145 | 2019-01-16 | 2025-10-24 |
Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Esophageal Neoplasms (1) · Mouth Neoplasms (1) · Oropharyngeal Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms (4) · Neoplasms by Site (4) · Head and Neck Neoplasms (3) · Carcinoma (2) · Carcinoma, Squamous Cell (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Urologic Neoplasms (2) · Adenocarcinoma (1)
camrelizumab (2) · Afatinib (1) · Biological Factors (1) · Immunotherapy (1) · Nivolumab (1) · pembrolizumab (1) · tislelizumab (1)
Fudan University (1) · Fujian Medical University Union Hospital (1) · Nanobiotix (1) · West China Hospital (1)
China (3) · United States (1)
Chun Chen, Dortor (1) · Pavel Tyan, MD (1) · Xiang Wang, MD (1) · Xingchen Peng (1) · Xudong Yao, MD (1) · Yushan Liu, MD (1)
PMID 15126782, PMID 15875784, PMID 17340590, PMID 22575238, PMID 23452187, PMID 24357284, PMID 24948466, PMID 25800393, PMID 25838375, PMID 27324428, PMID 28583311, PMID 28796558, PMID 29368638, PMID 29614760, PMID 30293387, PMID 3806806, PMID 41803866, PMID 9933432